New Technology– category –
-
BioNTech and Genentech Terminate Phase 2 Personalized Cancer Vaccine Trial Due to Survival Imbalance
Fierce Biotech USA Overview BioNTech and Genentech have cancelled their Phase 2 clinical trial for autogene cevumeran (BNT122), a personalized cancer vaccine targeting colorectal cancer patients, after an independent data safety monitori... -
Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate
Endpoints News USA Overview Novartis has disclosed the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS) complications in clinical trials of its CAR-T cell therapy, rapcabtagene aut... -
Winship Cancer Institute Launches Cellular Therapy Initiative to Scale Next-Gen Cancer Treatment Development
Winship Cancer Institute USA Overview Winship Cancer Institute has launched a "Cellular Therapy Initiative" to accelerate the development of next-generation cancer treatments, including expansion of its cGMP manufacturing capabilities. T... -
3D Bioprinting Market Drives Regenerative Medicine and Biomedical Innovation, Accelerated by AI Integration
The Business Research Company Global Overview The 3D bioprinting market is rapidly growing as a pivotal technology driving innovation in regenerative medicine and biomedical fields. This technology combines living cells, biomaterials, an... -
T-MAXIMUM Allogeneic CAR T-Therapy MT027 Receives FDA Fast Track Designation for Recurrent Glioblastoma
PR Newswire USA Overview T-MAXIMUM PHARMACEUTICAL announced that its B7-H3-targeted allogeneic CAR T-cell therapy, MT027, has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of recurrent glioblastoma. MT027 had ... -
Notre Dame Develops Machine Learning-Integrated Hybrid 3D Printing for Capillary-Scale Vascular Structures
RegMedNet USA Overview Researchers at the University of Notre Dame have successfully developed a hybrid 3D printing technology integrating machine learning to create capillary-scale microvascular structures. This novel approach demonstra... -
Precision BioSciences Initiates Clinical Trial for ARCUS Nuclease Gene Editing Therapy PBGENE-DMD in DMD
CRISPR Medicine News USA Overview Precision BioSciences has dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy (DMD). This therapy utilizes two ARCUS nucleases t... -
Novartis Halts CAR T-Cell Trials Following Patient Deaths in Experimental Therapy
pharmaphorum USA Overview Novartis has temporarily halted eight clinical trials for its experimental CAR T-cell therapy, rapcabtagene autoleucel (rap-cel), following the deaths of three patients from immune effector cell-associated hemop... -
China Approves Satri-Cel, World’s First CAR T-Cell Therapy for Claudin 18.2-Positive Gastric Cancer
PubMed China Overview China's National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction... -
FibroBiologics Secures U.S. Patent (No. 12,721,866) for Wound Healing with 3D Spheroid Fibroblasts, Targeting Chronic and Acute Wounds
Stock Titan USA Overview FibroBiologics announced the issuance of U.S. Patent No. 12,721,866 on September 1, 2026, for the therapeutic use of fibroblasts in wound healing. This patent covers the topical administration of 3D spheroid fibr...
